# OnCo record primary-cutaneous-anaplastic-large-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "primary-cutaneous-anaplastic-large-cell-lymphoma" ;
  schema:name "Primary cutaneous anaplastic large cell lymphoma"@en ;
  schema:alternateName "Primary cutaneous ALCL"@en, "pcALCL"@en, "Primary cutaneous anaplastic large-cell lymphoma"@en, "Cutaneous anaplastic large cell lymphoma"@en, "Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma"@en ;
  schema:description "A cutaneous T-cell lymphoma that appears as one or a few red-purple nodules on the skin, often ulcerated, which may shrink on their own. Despite cells that look alarming under the microscope it stays in the skin in almost everybody and is treated with surgery or local radiotherapy rather than chemotherapy."@en ;
  schema:url <https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anaplastic_large-cell_lymphoma> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1182/blood-2011-05-351346>, <https://doi.org/10.1016/S0190-9622(03)02484-8>, <https://doi.org/10.1038/bjc.2015.94> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/lymphomatoid-papulosis/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/mycosis-fungoides/>, <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/sezary-syndrome/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/palliative-radiotherapy/> ;
  onco:targets <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/methotrexate/> ;
  onco:terms <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-nodal-versus-extranodal/>, <https://onco.cc/terms/lymphoma-indolent-versus-aggressive/> ;
  onco:trials <https://onco.cc/trials/alcanza/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/cancers/lymphomatoid-papulosis/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/alcanza/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-skin-directed-therapy/> .